US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) and biotech firm Kymera Therapeutics have entered into a four-year strategic research and development collaboration to advance small molecule protein degraders against multiple targets.
This is the second major deal for Kymera, which last year linked up with UK pharma major GlaxoSmithKline (LSE: GSK) to work together on a limited number of protein degradation targets of mutual interest.
The collaboration will leverage Kymera’s expertise in targeted protein degradation and its proprietary Pegasus drug discovery platform and Vertex’s scientific, clinical, and regulatory capabilities to accelerate the development of first-in-class medicines for people with serious diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze